Idera Pharmaceuticals

Aug 21, 2020

Interstitial Cystitis market comprises robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly, such as KRP-116D (Kyorin Pharmaceutical), Certolizumab pegol/ Cimzia (UCB Pharma), LP-08 (Lipella Pharmaceuticals), GRT6010 (Grünenthal), ASP6294 (Astellas Pharma), and SI-...

Jun 02, 2020

Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555.  LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people g...

Dec 04, 2017

Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals. These receptors were first discovered in Drosophila melanogaster in the late 20th century which later led to the identification of mammalian homologs. Human TLR family consists of...

Sep 12, 2017

Idera Pharmaceuticals Present Positive Phase I Data for their Drug candidate IMO-2125 Idera Pharmaceuticals announced final results from the dose-selection phase of an ongoing Phase 1/2 trial investigating IMO-2125 in combination with ipilimumab (Yervoy). The combination dose-selection phase included 18 patients, al...